drugset / Trial / NCT04875806
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.
Timeline
- Start
- 2021-06-30
- Primary completion
- 2024-01-30
- Completion
- 2024-01-30
Outcome
Outcome not reported
Stopped: “Due to the limited activity in Phase 1, NextCure decided to discontinue development of the anti-B7-H4 antibody monotherapy trial (NC762-01) to move forward with a prioritized B7-H4 ADC program.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NC762 | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | NC762 | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | NC762 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | NC762 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | NC762 | Monoclonal antibody | 20 mg/kg | Intravenous |